期刊文献+

索拉非尼所致皮肤不良反应的护理对策 被引量:3

The nursing countermeasures of cutaneous adverse reaction resulting from taking sorafenib
下载PDF
导出
摘要 目的:探讨服用索拉非尼治疗导致皮肤不良反应的护理对策。方法:观察24例肝癌、肾癌和胆管细胞癌患者服用索拉非尼期间出现的皮肤不良反应,并对其进行分级、记录与统计分析,提出相应的护理对策。结果:24例患者中除1例因3度皮肤不良反应治疗无效而停药外,其余23例均未因皮肤不良反应加重而停用索拉非尼治疗。结论:针对性的护理对策有利于减轻索拉非尼所致皮肤不良反应,减轻患者痛苦,提高患者的生活质量。 Objective: To probe into the nursing countermeasures of cutaneous adverse reaction resulting from taking Sorafenib.Methods: The ocurring of cutaneous adverse reactions of 24 patients with liver,kidney and cholangiocellular carcinoma taken Sorafenib were observed during the treatment.Then,the cutaneous adverse reactions wwere graded,recorded and statistical analyzed the corresponding nursing countermeasures were put forward.Results: One patient suffered from grade III cutaneous adverse reaction and and the treatment failed,so Sorafenib was terminated;the remaining 23 cases weren't terminated the treatment with Sorafenib because of the worsening of cataneous adverse reactions.Conclusion: The specific nursing countermeasures conduce to lessen cutaneous adverse reaction,alleviate the suffering and improve the quality of life of the patients resulting from taking Sorafenib.
出处 《华夏医学》 CAS 2010年第5期621-623,共3页 Acta Medicinae Sinica
关键词 索拉非尼 皮肤 不良反应 护理 Sorafenib skin adverse reaction nursing
  • 相关文献

参考文献4

  • 1周爱萍,何志嵩,于世英,张沂平,杜春霞,孙永昆,石远凯,王金万,那彦群,孙燕.索拉非尼治疗转移性肾癌的临床研究[J].中华泌尿外科杂志,2009,30(1):10-14. 被引量:54
  • 2CHENG A L,KANG Y K,CHEN Z.Efficacy and safety of soratenib in patients in the Asia-Pacifio region with advanced hepatocellular carcinoma:a phase Ⅱ randomised,double-blind,place bo controlled trial[J].The ancet Onclolgy,2009(1):25-34.
  • 3MOLINA A MM,MOTZER R J.Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma[J].Clin Genitourin Cancer,2008,6(3):7-13.
  • 4管考鹏,马建辉,孙燕.索拉非尼的毒副作用及处理[J].癌症进展,2007,5(4):370-373. 被引量:39

二级参考文献25

  • 1周爱萍,孙燕.多靶点抗肿瘤新药索拉非尼的研究进展[J].癌症进展,2006,4(6):529-533. 被引量:57
  • 2Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs, 2003, 4: 757-763.
  • 3Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125-134.
  • 4Wilhelm SM, Carter C,Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109.
  • 5Awada A, Hendlisz A, Git T, et al. Safety and pharmacokinetics of BAY 43 9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005, 92: 1855-1861.
  • 6Ratain MJ, Eisen T, Stadler WM, et al. Phase Ⅱ placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24; 2505-2512.
  • 7Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oneol, 2002, 20, 289-296.
  • 8Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oneol, 2007, 25(Suppl) : 241.
  • 9Akaza H, Tsukamoto T, Murai M, et al. Phase Ⅱ study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. JpnJ Clin Oncol, 2007, 37: 755-762.
  • 10Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol, 2008, 158: 592-596.

共引文献90

同被引文献7

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部